Base de datos : MEDLINE
Búsqueda : B04.820.545.405.400.214 [Categoria DeCS]
Referencias encontradas : 13542 [refinar]
Mostrando: 1 .. 10   en el formato [Largo]

página 1 de 1355 va a la página                         

  1 / 13542 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29381710
Autor:Opriessnig T; Gauger PC; Gerber PF; Castro AMMG; Shen H; Murphy L; Digard P; Halbur PG; Xia M; Jiang X; Tan M
Dirección:The Roslin Institute and The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United Kingdom.
Título:Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model.
Fuente:PLoS One; 13(1):e0191739, 2018.
ISSN:1932-6203
País de publicación:United States
Idioma:eng
Resumen:Swine influenza A viruses (IAV-S) found in North American pigs are diverse and the lack of cross-protection among heterologous strains is a concern. The objective of this study was to compare a commercial inactivated A/H1N1/pdm09 (pH1N1) vaccine and two novel subunit vaccines, using IAV M2 ectodomain (M2e) epitopes as antigens, in a growing pig model. Thirty-nine 2-week-old IAV negative pigs were randomly assigned to five groups and rooms. At 3 weeks of age and again at 5 weeks of age, pigs were vaccinated intranasally with an experimental subunit particle vaccine (NvParticle/M2e) or a subunit complex-based vaccine (NvComplex/M2e) or intramuscularly with a commercial inactivated vaccine (Inact/pH1N1). At 7 weeks of age, the pigs were challenged with pH1N1 virus or sham-inoculated. Necropsy was conducted 5 days post pH1N1 challenge (dpc). At the time of challenge one of the Inact/pH1N1 pigs had seroconverted based on IAV nucleoprotein-based ELISA, Inact/pH1N1 pigs had significantly higher pdm09H1N1 hemagglutination inhibition (HI) titers compared to all other groups, and M2e-specific IgG responses were detected in the NvParticle/M2e and the NvComplex/M2e pigs with significantly higher group means in the NvComplex/M2e group compared to SHAMVAC-NEG pigs. After challenge, nasal IAV RNA shedding was significantly reduced in Inact/pH1N1 pigs compared to all other pH1N1 infected groups and this group also had reduced IAV RNA in oral fluids. The macroscopic lung lesions were characterized by mild-to-severe, multifocal-to-diffuse, cranioventral dark purple consolidated areas typical of IAV infection and were similar for NvParticle/M2e, NvComplex/M2e and SHAMVAC-IAV pigs. Lesions were significantly less severe in the SHAMVAC-NEG and the Inact/pH1N1pigs. Under the conditions of this study, a commercial Inact/pH1N1 specific vaccine effectively protected pigs against homologous challenge as evidenced by reduced clinical signs, virus shedding in nasal secretions and oral fluids and reduced macroscopic and microscopic lesions whereas intranasal vaccination with experimental M2e epitope-based subunit vaccines did not. The results further highlight the importance using IAV-S type specific vaccines in pigs.
Tipo de publicación:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
Nombre de substancia:0 (Influenza Vaccines)


  2 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29458547
Autor:Growcott EJ; Bamba D; Galarneau JR; Leonard VHJ; Schul W; Stein D; Osborne CS
Dirección:1​Novartis Institutes for Biomedical Research, Infectious Disease, Emeryville, CA, USA.
Título:The effect of P38 MAP kinase inhibition in a mouse model of influenza.
Fuente:J Med Microbiol; 67(3):452-462, 2018 Mar.
ISSN:1473-5644
País de publicación:England
Idioma:eng
Resumen:PURPOSE: Influenza viruses are a common cause of human respiratory infections, resulting in epidemics of high morbidity and mortality. We investigated the effect of a novel mitogen-activated protein kinase (MAPK) inhibitor in vitro and in a murine influenza model to further explore whether p38 MAPK inhibition could reduce viral replication. METHODS: In vitro, the antiviral effect of p38 MAPK inhibitor BCT194 was evaluated in differentiated human bronchial epithelial cells (HBECs); in vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with BCT197 (a closely related p38 MAPK inhibitor with an IC50 value of<1 µM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24 h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically.Results/Key findings. p38MAP kinase inhibition with BCT194 had no impact on influenza replication in HBECs. When examining BCT197 in vivo, and comparing to vehicle-treated animals, reduced weight loss, improvement in survival and lack of impaired viral control was observed at BCT197 concentrations relevant to those being used in clinical trials of acute exacerbations of chronic obstructive pulmonary disease; at higher concentrations of BCT197 these effects were reduced. CONCLUSIONS: Compared to vehicle treatment, BCT197 (administered at a clinically relevant concentration) improved outcomes in a mouse model of influenza. This is encouraging given that the use of innate inflammatory pathway inhibitors may raise concerns of negative effects on infection regulation.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antiviral Agents); 0 (Cytokines); 0 (Enzyme Inhibitors); 20O93L6F9H (Oseltamivir); 7S5I7G3JQL (Dexamethasone); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)


  3 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28456530
Autor:Zhang Y; Wu P; Feng L; Yang P; Pan Y; Feng S; Qin Y; Zheng J; Puig-Barberà J; Muscatello D; MacIntyre R; Cowling BJ; Yu H; Wang Q
Dirección:Institute of Infectious Diseases and Endemic Diseases Control, Beijing Center for Disease Prevention and Control, Beijing, China; School of Public Health and Community Medicine, The University of New South Wales, Sydney, NSW 2052, Australia.
Título:Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China.
Fuente:Vaccine; 35(23):3129-3134, 2017 05 25.
ISSN:1873-2518
País de publicación:Netherlands
Idioma:eng
Resumen:BACKGROUND: Vaccination is recommended to prevent influenza virus infection and associated complications. This study aimed to estimate the influenza vaccine effectiveness (VE) against hospitalization in the 2015/16 season in Beijing. METHODS: Patients who were hospitalized in the 5 study hospitals between 1 Oct 2015 and 15 May 2016 were recruited. Influenza vaccination status was obtained for PCR-confirmed influenza patients and the selected controls who tested negative for the virus. Conditional logistic regression was used to estimate the influenza VE matching by calendar week, and adjusting for age, study sites, underlying medical conditions, smoking status, and hospital admissions over the past 12months. RESULTS: The overall VE was -37.9% (95% CI: -103.3, 6.5) against laboratory-confirmed influenza-associated hospitalization. The 2015-16 seasonal vaccine was had -61.9% (95% CI: -211.9, 15.9), -5.4% (95% CI: -108.1, 46.6) and -45.2% (95% CI: -152.6, 16.5) effectiveness to prevent infection from A(H1N1)pdm09, A(H3N2) and influenza B, respectively. CONCLUSIONS: Influenza vaccination did not show effective protection against hospitalization with influenza in 2015/16 season in Beijing.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.; RESEARCH SUPPORT, NON-U.S. GOV'T
Nombre de substancia:0 (Influenza Vaccines)


  4 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28453845
Autor:Martínez-Baz I; Casado I; Navascués A; Díaz-González J; Aguinaga A; Barrado L; Delfrade J; Ezpeleta C; Castilla J
Dirección:Instituto de Salud Pública de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Título:Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus.
Fuente:J Infect Dis; 215(6):847-855, 2017 03 15.
ISSN:1537-6613
País de publicación:United States
Idioma:eng
Resumen:Background: The 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) vaccine component has remained unchanged from 2009. We estimate the effectiveness of current and prior inactivated influenza A(H1N1)pdm09 vaccination from influenza seasons 2010-2011 to 2015-2016. Methods: Patients attended with influenza-like illness were tested for influenza. Four periods with continued A(H1N1)pdm09 circulation were included in a test-negative design. Results: We enrolled 1278 cases and 2343 controls. As compared to individuals never vaccinated against influenza A(H1N1)pdm09, the highest effectiveness (66%; 95% confidence interval, 49%-78%) was observed in those vaccinated in the current season who had received 1-2 prior doses. The effectiveness was not statistically lower in individuals vaccinated in the current season only (52%) or in those without current vaccination and >2 prior doses (47%). However, the protection was lower in individuals vaccinated in the current season after >2 prior doses (38%; P = .009) or those currently unvaccinated with 1-2 prior doses (10%; P < .001). Current-season vaccination improved the effect in individuals with 1-2 prior doses and did not modify significantly the risk of influenza in individuals with >2 prior doses. Conclusion: Current vaccination or several prior doses were needed for high protection. Despite the decreasing effect of repeated vaccination, current-season vaccination was not inferior to no current-season vaccination.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Influenza Vaccines)


  5 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PMID:27770828
Autor:Álvarez-Lerma F; Marín-Corral J; Vila C; Masclans JR; González de Molina FJ; Martín Loeches I; Barbadillo S; Rodríguez A; H1N1 GETGAG/SEMICYUC Study Group
Dirección:Service of Intensive Care Medicine, Hospital del Mar, Passeig Marítim 25-29, E-08003, Barcelona, Spain. FAlvarez@parcdesalutmar.cat.
Título:Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome.
Fuente:Crit Care; 20(1):337, 2016 Oct 23.
ISSN:1466-609X
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: Patients infected with influenza A (H1N1)pdm09 virus requiring admission to the ICU remain an important source of mortality during the influenza season. The objective of the study was to assess the impact of a delay in diagnosis of community-acquired influenza A (H1N1)pdm09 virus infection on clinical outcome in critically ill patients admitted to the ICU. METHODS: A prospective multicenter observational cohort study was based on data from the GETGAG/SEMICYUC registry (2009-2015) collected by 148 Spanish ICUs. All patients admitted to the ICU in which diagnosis of influenza A (H1N1)pdm09 virus infection had been established within the first week of hospitalization were included. Patients were classified into two groups according to the time at which the diagnosis was made: early (within the first 2 days of hospital admission) and late (between the 3rd and 7th day of hospital admission). Factors associated with a delay in diagnosis were assessed by logistic regression analysis. RESULTS: In 2059 ICU patients diagnosed with influenza A (H1N1)pdm09 virus infection within the first 7 days of hospitalization, the diagnosis was established early in 1314 (63.8 %) patients and late in the remaining 745 (36.2 %). Independent variables related to a late diagnosis were: age (odds ratio (OR) = 1.02, 95 % confidence interval (CI) 1.01-1.03, P < 0.001); first seasonal period (2009-2012) (OR = 2.08, 95 % CI 1.64-2.63, P < 0.001); days of hospital stay before ICU admission (OR = 1.26, 95 % CI 1.17-1.35, P < 0.001); mechanical ventilation (OR = 1.58, 95 % CI 1.17-2.13, P = 0.002); and continuous venovenous hemofiltration (OR = 1.54, 95 % CI 1.08-2.18, P = 0.016). The intra-ICU mortality was significantly higher among patients with late diagnosis as compared with early diagnosis (26.9 % vs 17.1 %, P < 0.001). Diagnostic delay was one independent risk factor for mortality (OR = 1.36, 95 % CI 1.03-1.81, P < 0.001). CONCLUSIONS: Late diagnosis of community-acquired influenza A (H1N1)pdm09 virus infection is associated with a delay in ICU admission, greater possibilities of respiratory and renal failure, and higher mortality rate. Delay in diagnosis of flu is an independent variable related to death.
Tipo de publicación:JOURNAL ARTICLE


  6 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29212467
Autor:Yu X; Wang C; Chen T; Zhang W; Yu H; Shu Y; Hu W; Wang X
Dirección:Department of Biostatistics, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, 200231 Xuhui District, Shanghai, China.
Título:Excess pneumonia and influenza mortality attributable to seasonal influenza in subtropical Shanghai, China.
Fuente:BMC Infect Dis; 17(1):756, 2017 12 07.
ISSN:1471-2334
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: Disease burden attributable to influenza is substantial in subtropical regions. Our study aims to estimate excess pneumonia and influenza (P&I) mortality associated with influenza by subtypes/lineages in Shanghai, China, 2010-2015. METHODS: Quasi-Poisson regression models were fitted to weekly numbers of deaths from causes coded as P&I for Shanghai general and registered population. Three proxies for influenza activity were respectively used as an explanatory variable. Long-term trend, seasonal trend and absolute humidity were adjusted for as confounding factors. The outcome measurements of excess P&I mortality associated with influenza subtypes/lineages were derived by subtracting the baseline mortality from fitted mortality. RESULTS: Excess P&I mortality associated with influenza were 0.22, 0.30, and 0.23 per 100,000 population for three different proxies in Shanghai general population, lower than those in registered population (0.34, 0.48, and 0.36 per 100,000 population). Influenza B (Victoria) lineage did not contribute to excess P&I mortality (P = 0.206) while influenza B (Yamagata) lineage did (P = 0.044). Influenza-associated P&I mortality was high in the elderly population. CONCLUSIONS: Seasonal influenza A virus had a higher P&I mortality than influenza B virus, while B (Yamagata) lineage is the dominant lineage attributable to P&I mortality.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T


  7 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29202715
Autor:Talla Nzussouo N; Duque J; Adedeji AA; Coulibaly D; Sow S; Tarnagda Z; Maman I; Lagare A; Makaya S; Elkory MB; Kadjo Adje H; Shilo PA; Tamboura B; Cisse A; Badziklou K; Maïnassara HB; Bara AO; Keita AM; Williams T; Moen A; Widdowson MA; McMorrow M
Dirección:Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. tallus5@yahoo.fr.
Título:Epidemiology of influenza in West Africa after the 2009 influenza A(H1N1) pandemic, 2010-2012.
Fuente:BMC Infect Dis; 17(1):745, 2017 12 04.
ISSN:1471-2334
País de publicación:England
Idioma:eng
Resumen:BACKGROUND: Over the last decade, capacity for influenza surveillance and research in West Africa has strengthened. Data from these surveillance systems showed influenza A(H1N1)pdm09 circulated in West Africa later than in other regions of the continent. METHODS: We contacted 11 West African countries to collect information about their influenza surveillance systems (number of sites, type of surveillance, sampling strategy, populations sampled, case definitions used, number of specimens collected and number of specimens positive for influenza viruses) for the time period January 2010 through December 2012. RESULTS: Of the 11 countries contacted, 8 responded: Burkina Faso, Cote d'Ivoire, Mali, Mauritania, Niger, Nigeria, Sierra Leone and Togo. Countries used standard World Health Organization (WHO) case definitions for influenza-like illness (ILI) and severe acute respiratory illness (SARI) or slight variations thereof. There were 70 surveillance sites: 26 SARI and 44 ILI. Seven countries conducted SARI surveillance and collected 3114 specimens of which 209 (7%) were positive for influenza viruses. Among influenza-positive SARI patients, 132 (63%) were influenza A [68 influenza A(H1N1)pdm09, 64 influenza A(H3N2)] and 77 (37%) were influenza B. All eight countries conducted ILI surveillance and collected 20,375 specimens, of which 2278 (11%) were positive for influenza viruses. Among influenza-positive ILI patients, 1431 (63%) were influenza A [820 influenza A(H1N1)pdm09, 611 influenza A(H3N2)] and 847 (37%) were influenza B. A majority of SARI and ILI case-patients who tested positive for influenza (72% SARI and 59% ILI) were children aged 0-4 years, as were a majority of those enrolled in surveillance. The seasonality of influenza and the predominant influenza type or subtype varied by country and year. CONCLUSIONS: Influenza A(H1N1)pdm09 continued to circulate in West Africa along with influenza A(H3N2) and influenza B during 2010-2012. Although ILI surveillance systems produced a robust number of samples during the study period, more could be done to strengthen surveillance among hospitalized SARI case-patients. Surveillance systems captured young children but lacked data on adults and the elderly. More data on risk groups for severe influenza in West Africa are needed to help shape influenza prevention and clinical management policies and guidelines.
Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.


  8 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PMID:29389094
Autor:Myers N
Título:Policy Making to Build Relationships: A Grounded Theory Analysis of Interviews and Documents Relating to H1N1, Ebola, and the U.S. Public Health Preparedness Network.
Fuente:J Health Hum Serv Adm; 39(3):313-56, 2016.
ISSN:1079-3739
País de publicación:United States
Idioma:eng
Resumen:In the last five years, the American public health emergency preparedness and response system has been tested by two significant threats, H1N1 and Ebola. While neither proved as dangerous as initially feared, these viruses highlighted on-going issues with collaborations in the field of public health and health care. Strengths were identified within the network, but also challenges that must be resolved before the U.S. faces a major pandemic. Employing interview data from public health emergency response practitioners and documentary evidence from the H1N1 and Ebola responses, this qualitative analysis uses the grounded theory approach to identify key areas for collaborative improvement. The grounded theory developed calls for a stronger policy framework at the federal level to facilitate more collaboration between U.S. agencies and facilitate more collaboration at the state and local level.
Tipo de publicación:JOURNAL ARTICLE


  9 / 13542 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29447145
Autor:Budd AP; Wentworth DE; Blanton L; Elal AIA; Alabi N; Barnes J; Brammer L; Burns E; Cummings CN; Davis T; Flannery B; Fry AM; Garg S; Garten R; Gubareva L; Jang Y; Kniss K; Kramer N; Lindstrom S; Mustaquim D; O'Halloran A; Olsen SJ; Sessions W; Taylor C; Xu X; Dugan VG; Katz J; Jernigan D
Dirección:Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.
Título:Update: Influenza Activity - United States, October 1, 2017-February 3, 2018.
Fuente:MMWR Morb Mortal Wkly Rep; 67(6):169-179, 2018 Feb 16.
ISSN:1545-861X
País de publicación:United States
Idioma:eng
Resumen:Influenza activity in the United States began to increase in early November 2017 and rose sharply from December through February 3, 2018; elevated influenza activity is expected to continue for several more weeks. Influenza A viruses have been most commonly identified, with influenza A(H3N2) viruses predominating, but influenza A(H1N1)pdm09 and influenza B viruses were also reported. This report summarizes U.S. influenza activity* during October 1, 2017-February 3, 2018, and updates the previous summary (1).
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antiviral Agents)


  10 / 13542 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29447141
Autor:Flannery B; Chung JR; Belongia EA; McLean HQ; Gaglani M; Murthy K; Zimmerman RK; Nowalk MP; Jackson ML; Jackson LA; Monto AS; Martin ET; Foust A; Sessions W; Berman L; Barnes JR; Spencer S; Fry AM
Título:Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.
Fuente:MMWR Morb Mortal Wkly Rep; 67(6):180-185, 2018 Feb 16.
ISSN:1545-861X
País de publicación:United States
Idioma:eng
Resumen:In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1). During each influenza season since 2004-05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent laboratory-confirmed influenza associated with medically attended acute respiratory illness (ARI). This report uses data from 4,562 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 2, 2017-February 3, 2018. During this period, overall adjusted vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended ARI was 36% (95% confidence interval [CI] = 27%-44%). Most (69%) influenza infections were caused by A(H3N2) viruses. VE was estimated to be 25% (CI = 13% to 36%) against illness caused by influenza A(H3N2) virus, 67% (CI = 54%-76%) against A(H1N1)pdm09 viruses, and 42% (CI = 25%-56%) against influenza B viruses. These early VE estimates underscore the need for ongoing influenza prevention and treatment measures. CDC continues to recommend influenza vaccination because the vaccine can still prevent some infections with currently circulating influenza viruses, which are expected to continue circulating for several weeks. Even with current vaccine effectiveness estimates, vaccination will still prevent influenza illness, including thousands of hospitalizations and deaths. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Influenza Vaccines)



página 1 de 1355 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud